Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.48 |
| ▸ | WNT3A | P56704 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 5/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CLK3 | P49761 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5990339 | 1.00 | ROCK2 (0.48) | ROCK2ROCK1CTNNB1WNT3ARAB9A | |
| Fumaric Acid SCHEMBL6361834 | 0.87 | FGFR1 (0.57) | RAB9ANPC1ESR1CLK2DYRK1A | |
| Fumaric Acid SCHEMBL6361838 | 0.87 | FGFR1 (0.57) | RAB9ANPC1ESR1CLK2DYRK1A | |
| SCHEMBL29520931 | 0.86 | ROCK2 (0.59) | ROCK2ROCK1CTNNB1WNT3ARAB9A | |
| SCHEMBL277777 | 0.86 | ROCK2 (0.59) | ROCK2ROCK1CTNNB1WNT3ARAB9A | |
| Hydrochloric Acid SCHEMBL27782875 | 0.84 | ROCK2 (0.57) | ROCK2ROCK1CTNNB1WNT3ARAB9A | |
| SCHEMBL25228737 | 0.79 | ESR1 (0.60) | ESR1NEK2 | |
| Indazole SCHEMBL3410547 | 0.78 | HSP90AA1 (0.68) | ROCK2ROCK1CTNNB1WNT3ARAB9A | |
| Indazole SCHEMBL3410555 | 0.78 | HSP90AA1 (0.68) | ROCK2ROCK1CTNNB1WNT3ARAB9A | |
| Indazole SCHEMBL5215610 | 0.78 | HSP90AA1 (0.68) | ROCK2ROCK1CTNNB1WNT3ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052431-A1 | 5-Hydroxy indazole derivatives for treating glaucoma | MAY JESSE A | 2006-03-09 | — | — | US | disclosed |
| US-7005443-B1 | 5-Hydroxy indazole derivatives for treating glaucoma | ALCON, INC. (CH) | 2006-02-28 | — | — | US | disclosed |
| EP-1268439-A1 | 5-HYDROXY INDAZOLE DERIVATIVES FOR TREATING GLAUCOMA | Alcon Inc. (CH) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001070701-A1 | 5-HYDROXY INDAZOLE DERIVATIVES FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052431-A1 | 5-Hydroxy indazole derivatives for treating glaucoma | PTGIS, PTGIR, PDE3A | MEN1 4099/4885KMT2A 4412/4885ROCK2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.